No Data
No Data
Express News | Ionis Pharmaceuticals: 97% Of Patients in Medium and High Dose Groups Saw Improvement in Overall Angelman Syndrome Symptoms
Express News | Ionis Pharmaceuticals Inc - to Initiate Phase 3 Development in H1 2025
Express News | Ionis Announces Positive Detailed Results From the Halos Study of Ion582 in People With Angelman Syndrome
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
Ionis to Hold Second Quarter 2024 Financial Results Webcast
Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern TimeCARLSBAD, Calif., July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live
Express News | Ionis Pharmaceuticals Has Completed Enrollment In The Pivotal Trial Of Zilganersen (ION373) For The Treatment Of Children And Adults With A Rare, Progressive Neurological Disorder Known As Alexander Disease. Topline Data Are Anticipated In 2H Of 2025
No Data